MHRA Greenlights New Drug for Rare Brain-Damaging Disorder
The Medicines and Healthcare products Regulatory Agency (MHRA) has given the thumbs-up for fosdenopterin (Nulibry) to treat Molybdenum Cofactor Deficiency (MoCD) Type A, a rare and devastating genetic condition.
What is MoCD Type A?
This rare disorder stems from a faulty MOCS1 gene, which stops the body from producing a crucial molecule called cyclic pyranopterin monophosphate (cPMP). Without cPMP, toxic sulphites build up, attacking the brain and causing serious damage. Newborns with MoCD Type A often suffer seizures, uncontrolled movements, and trouble feeding.
Fosdenopterin Gets the Nod
- The MHRA has approved fosdenopterin for use across Great Britain.
- The move follows a European Commission decision, backed by expert advice from the Committee for Medicinal Products for Human Use (CHMP).
- This process, known as the EC Decision Reliance Procedure, fast-tracks promising treatments after thorough checks.
Safety and How It Works
- Patient safety remains top priority for the MHRA throughout the approval process.
- Fosdenopterin is given intravenously as a 9.5 mg powder solution via catheter.
- Regulators have met strict safety and quality standards and will continue monitoring closely.
Why This Matters
MoCD Type A is life-threatening and was previously untreatable. Fosdenopterin offers a lifeline, reducing toxic sulphite levels to protect the brain and improve outcomes.
This breakthrough drug holds fresh hope for families battling this relentless condition. But as always, vigilance on side effects and safety is essential moving forward.
